BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms (Q39113216)

9 September 2017

title

BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms (English)

1 reference

9 September 2017

1 reference

9 September 2017

T Kouzarides

0 references

B Gottgens

0 references

A R Green

1 reference

9 September 2017

B S Wyspiańska

1 reference

9 September 2017

I Barbieri

1 reference

9 September 2017

J Nangalia

1 reference

9 September 2017

A Godfrey

1 reference

9 September 2017

F J Calero-Nieto

1 reference

9 September 2017

S Robson

1 reference

9 September 2017

I Rioja

1 reference

9 September 2017

J Li

1 reference

9 September 2017

M Wiese

1 reference

9 September 2017

E Cannizzaro

1 reference

9 September 2017

M A Dawson

1 reference

9 September 2017

B Huntly

1 reference

9 September 2017

R K Prinjha

1 reference

9 September 2017

publication date

9 August 2013

1 reference

9 September 2017

1 reference

9 September 2017

1 reference

9 September 2017

1 reference

9 September 2017

page(s)

88-97

1 reference

Polycythemia vera: stem-cell and probable clonal origin of the disease

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Bromodomains as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Targeting MYC dependence in cancer by inhibiting BET bromodomains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Aberrant induction of LMO2 by the E2A-HLF chimeric transcription factor and its implication in leukemogenesis of B-precursor ALL with t(17;19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

A previously unrecognized promoter of LMO2 forms part of a transcriptional regulatory circuit mediating LMO2 expression in a subset of T-acute lymphoblastic leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

The role of jak2a in zebrafish hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.234

Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia

21 January 2018

1 reference

12 December 2020

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders

1 reference

12 December 2020

Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell

1 reference

12 December 2020

HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias.

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2013.234

1 reference

Dimensions Publication ID

9 September 2017

1038473277

0 references

1 reference